CONCORD, Calif.--(BUSINESS WIRE)--July 26, 2005--In conjunction
with Cerus Corporation's (Nasdaq:CERS) report of its second quarter
financial results, a live webcast will be made of its conference call
hosted by Claes Glassell, president and CEO, William J. Dawson, vice
president, finance and CFO, Larry M. Corash, vice president and chief
medical officer, and David N. Cook, vice president, research and
development.
What: Financial results, with an update on progress and future
outlook
When: Tuesday, August 2, 2005 at 4:30 p.m. ET
Where: http://www.cerus.com
Contact: Ruey-Li Hwang / Cerus Corporation, 925-288-6017
Cerus Corporation's second quarter release will be issued on
August 2, 2005 at 4:00 p.m. EDT and will be made available at
http://www.cerus.com. The company will archive the earnings release
audio replay as well as the press release on the company's website. The conference call is protected by copyright. It cannot be
recorded or rebroadcast without Cerus' permission. About Cerus Corporation Cerus Corporation is developing novel products for cancer,
infectious disease and blood safety based on multiple, innovative
technology platforms. The company is building a pipeline of next
generation cancer immunotherapies by combining its proprietary
attenuated Listeria vector platform with promising disease antigens.
These products are designed to stimulate innate and T cell immune
pathways, generating highly potent anti-tumor responses. Cerus is
applying its Helinx technology to develop the INTERCEPT Blood System,
which is designed to enhance the safety of blood components through
pathogen inactivation. The company's strategy is to leverage the broad
potential of its technologies and products through alliances. Cerus'
partners to date include MedImmune and Johns Hopkins University for
cancer immunotherapy, and Baxter International and BioOne for the
INTERCEPT Blood System. Helinx is a trademark of Cerus Corporation. Baxter and INTERCEPT are trademarks of Baxter International Inc.
CONTACT: Cerus Corporation
Ruey-Li Hwang, 925-288-6017
SOURCE: Cerus Corporation
|